Background. We explore the temporal and regimen-specific changes of HIV-1 drug resistance in a large cohort of antiretroviral-naive individuals starting highly active antiretroviral therapy (HAART).
Highly active antiretroviral therapy (HAART) has led to a dramatic decrease in AIDS-related comorbidity and mortality [1] [2] [3] . However, the success of HAART can be compromised by the development of HIV drug resistance [4, 5] . Antiretroviral resistance is an independent risk factor for virologic failure in HIV-1-infected populations [4, 6, 7] . Drug-resistance testing is now widely recommended in HIV therapy monitoring to detect the development of resistance to antiretrovirals and make appropriate regimen changes [8] .
Several individual factors have been associated with the development of HIV-1 drug resistance during HAART, including incomplete adherence to therapy [9 -12] , high baseline plasma viral load (pVL), and low CD4 cell count [12, 13] . However, there has been limited research on how the simultaneous presence of these factors and their interactions affect the development of antiretroviral resistance [7, 12] . Recent studies have shown that the relationship between adherence and resistance is complex [12, 14] . The accumulation of resistance mutations across all levels of adherence was greater in treatment-naive individuals beginning HAART than in those who were treatment experienced [12, 15] . The heterogeneity in the relationship between adherence and resistance in antiretroviral-exposed and -naive populations has been explored via computer simulations [16] .
The relationship between adherence and resistance is also dependent on the individual drug classes used in combination therapy [14, 17, 18] , with discrepancies between the adherence-resistance relationships for nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) being at least partially explained by differences in the replicative capacity of drug-resistant versus wild-type virus in the presence of clinically relevant drug levels for each drug, respectively [14] . Recommendations for the optimal application of HAART have varied over time [19 -21] as therapies have evolved to become more convenient and tolerable. One particularly relevant change has been the widespread shift of international guidelines in favor of low-dose ritonavir as a PI "boosting" agent when PI-based HAART is used [22, 23] . The use of boosted PIs have led to improved virological suppression, as detailed in clinical trials [22, 24, 25] and cohort studies [26] , as well as improved clinical outcomes in cohort studies in observational settings [27] . However, the impact of boosted PI-based regimens versus nonboosted PI-based and NNRTI-based regimens on the development of HIV drug resistance mutations remains to be defined in a population-based setting.
The objective of the present study was to characterize the probability of the development of drug resistance in drug-naive individuals starting HAART in the modern era, adjusting for the simultaneous effects of adherence, pVL, and initial HAART regimen. We based our analysis on data from a large populationbased cohort of HIV-1-infected antiretroviral-naive adults initiating HAART in British Columbia, Canada, between 1 August 1996 and 30 November 2004.
METHODS

HIV/AIDS drug distribution program. The British Columbia
Centre for Excellence in HIV/AIDS (BC-CfE) distributes antiretroviral agents at no cost to all eligible HIV-infected individuals through its drug distribution program, the HIV/AIDS Drug Treatment Program (BC-CfE DTP). This program has been described in detail elsewhere [28] . ART is distributed according to the specific guidelines generated by the Therapeutic Guidelines Committee. The BC-CfE's guidelines have been regularly updated and remain consistent with those of the International AIDS Society-USA [19, 20, 29] . The BC-CfE DTP has received ethical approval from the University of British Columbia Ethics Review Committee at its St. Paul's Hospital site.
Study participants. Eligible study participants were 18 years old and were naive to ART when they started HAART (consisting of 2 nucleosides/nucleotides plus either a nonboosted PI, an NNRTI, or a PI plus Ͻ800 mg of ritonavir [boosted PI]). Participants started treatment between 1 August 1996 and 30 November 2004 and were followed up until 30 November 2005 (n ϭ 2350, with median follow-up of 4.8 years and a total of 6066 tests). Participants must have had a CD4 cell count and pVL measurement within 6 months of the first antiretroviral start date. Study data from eligible participants were extracted from the BC-CfE's monitoring and evaluation system to form the HOMER (HAART Observational Medical Evaluation and Research) cohort. The characteristics of this study population have been extensively described elsewhere [28, 30] .
Data collection. HIV-positive individuals receiving ART in British Columbia are entered into an Oracle-based monitoring and evaluation system that uses standardized indicators to prospectively track antiretroviral use and the clinical health status of these individuals. Physicians enrolling an HIV-infected individ- ual into the system must complete a drug request enrollment prescription form, which compiles information on the participant's address, past HIV-specific drug history, CD4 cell counts, pVL, current drug requests, and the enrolling physician. A qualified practitioner reviews all requests to verify that they follow the therapeutic guidelines outlined by the BC-CfE. Approved prescriptions are renewed every 1 to 3 months. The BC-CfE recommends that pVLs and CD4 cell counts be monitored at baseline, at 4 weeks after the start of ART, and every 3 months thereafter. pVLs are determined using the Roche Amplicor Monitor assay (Roche Diagnostics) by either the standard method or the ultrasensitive adaptation (since 1999). CD4 cell counts are measured by flow cytometry, followed by fluorescent monoclonal antibody analysis (Beckman Coulter).
Resistance testing was performed on stored pVL samples extracted manually or automatically using guanidinium-based buffer, followed by ethanol washes. Protease (PR) and reversetranscriptase (RT) genes were amplified from plasma HIV-1 RNA by nested RT polymerase chain reaction (PCR), as described elsewhere [12] . PCR products were sequenced in both the 5' and 3' directions using an ABI automated sequencer, and a consensus sequence was generated. Results of the genotyping analysis are reported here as amino acid changes in the HIV PR and RT genes with respect to a wild-type reference sequence (HIV HXB2; GenBank accession number K03455). Samples were assigned to 1 of 4 resistance categories on the basis of a modification of the International AIDS Society-USA table [31] . Samples were considered to be resistant if they displayed 1 or more major resistance mutations in any of the following 4 categories: lamivudine (184I/V); any other nucleoside reversetranscriptase inhibitors (NRTIs; 41L, 62V, 65R, 67N, 69D or insertion, 70R, 74V, 75I, 151M, 210W, 215F/Y, or 219E/Q); any NNRTIs (100I, 103N, 106A/M, 108I, 181C/I, 188C/H/L, 190A/S, P225H, M230L, or 236L); and any PIs (30N, 46I/L, 48V, 50L/V, 54V/L/M, 82A/F/S/T, 84V, or 90M). Lamivudine resistance was analyzed as a separate category because of the very common appearance of this mutation and the lack of cross-resistance conferred to other NRTIs. The percentage of samples that were obtained while individuals were being actively prescribed any ART were as follows: 82% for first lamivudine resistance, 78% for other NRTIs, 84% for NNRTIs, and 81% for PIs. Because genotyping does not yield consistently successful results for samples with low pVL, samples with a pVL Ͻ1000 copies/mL were not systematically genotyped and were assumed to have no drugresistance mutations. We conducted a sensitivity analysis to assess the impact of our assumption that samples with a pVL Ͻ1000 copies/mL harbored no drug-resistance mutations. For the sensitivity analysis, we repeated the original analysis only for those individuals with at least 1 sample that had a pVL 1000 copies/mL. Resistance data from those who started therapy between August 1996 and September 1999 have been reported elsewhere [12] .
Of the 2350 individuals included in this analysis, at least 1 available pretherapy genotype was available for 1426 (61%). Primary resistance was assessed using a standardized list of mutations suitable for transmitted resistance surveillance [32] . From the earliest available pretherapy genotypes, 131 (9.2 %) showed some evidence of transmitted resistance. A sensitivity analysis was conducted that eliminated those individuals who were known to have transmitted resistance, leaving 1295 patients.
For each individual, the median number of genotypes that could possibly have been included in the analysis for which data was unavailable was 0 (interquartile range [IQR], 0 -1) and the median number completed was 1 (IQR, 0 -2). A total of 1433 (61.0%) of individuals had all possible genotypes completed.
Outcome measures and predictor variables. The primary outcome in this analysis was the emergence of drug resistance in any of the four resistance categories described previously (yes vs. no). The following baseline predictor variables were investigated: age, sex, CD4 cell count, pVL (log 10 transformed), first regimen, AIDS diagnosis, history of injection drug use, year of first therapy, and adherence. Estimates of adherence to ART were based on medications actually dispensed, not prescribed. For this study, we limited our measure of adherence to the first year of therapy, estimated by dividing the number of months of medications dispensed by the number of months of follow-up. This measure of adherence has been found to be independently associated with HIV suppression and survival among HIVinfected persons enrolled in the BC-CfE DTP [33, 34] . Adherence was categorized as 0% to Ͻ40%, 40% to Ͻ80%, 80% to Ͻ95% and 95%. Because pVL was measured over time starting in 1996, our baseline pVLs were obtained on the basis of the standard pVL assay, and our last measurements were obtained on the basis of the ultrasensitive pVL assay; thus, our upper and lower limits of pVLs ranged over time from 500 and 1 ϫ 10 6 to 50 and 1 ϫ 10 5 copies/mL. Therefore, our pVL measurements were recoded to range from 500 to 1 ϫ 10 5 copies/mL in order to standardize the viral load range over time.
Statistical analyses. An exploratory logistic regression model was developed for identifying which patient characteristics were most influential in the development of drug resistance during ART. A backward stepwise technique was used in the selection of covariates. The area under the receiver operating characteristic curve was used to measure the model's ability to discriminate between those in whom resistance developed versus those in whom it did not [35] . Categorical variables were compared using the 2 or Fisher's exact test, and continuous variables were compared using the Wilcoxon rank-sum test. For the purposes of analysis, we followed the intent-to-treat principle, with subjects retained in their initial treatment groups irrespective of whether participants subsequently switched to regimens that were available later. This approach provides a conservative estimate of the true treatment effect. All analyses were performed using SAS software (version 9.1.3, service pack 3).
RESULTS
Demographic characteristics.
Between August 1996 and November 2004, a total of 2350 antiretroviral-naive participants (81.6% males) at least 18 years old started triple-combination therapy in British Columbia and were eligible to participate in this study. Of these patients, 991 (42%) individuals initiated nonboosted PI-based regimens, 475 (20%) initiated boosted PI-based regimens, and 884 (38%) initiated NNRTI-based regimens. A further breakdown of patients' antiretroviral regimens, stratified by years of initiation, is provided in table 1. The temporal change toward increasing prevalence of ritonavir-boosted regimens in recent years reflects the changes in treatment guidelines over time. During a median of 4.8 years (IQR, 2.7-10.0) of follow-up, a total of 6066 resistance tests were done, and resistance to at least one drug category developed in 650 (28%) patients. As shown in table 2, the development of drug resistance was associated with a higher pVL, history of injection drug use, NNRTI-based regimens, starting therapy in 1996 -1998, age, and higher adherence levels (P Ͻ .0001). Sex, AIDS diagnosis, and CD4 cell count were not significantly associated with the development of drug resistance. Probability of drug-resistance development. Table 3 shows the results for univariate and multivariate associations between the emergence of drug resistance and several baseline factors. The univariate analysis for baseline characteristics showed that age, pVL, history of injection drug use, first regimen, year of first therapy, and adherence were associated with the development of drug resistance. The multivariate model predicted no difference in the odds of the development of key resistance mutations between nonboosted PI-based regimens (reference group) and NNRTI-based HAART regimens (odds ratio (table 3) . Figures 1 and 2 show estimated model-based probabilities of the development of resistance by adherence level and several covariates of interest. Figure 1a demonstrates a nonlinear relationship between adherence and drug resistance, with the development of resistance being more likely in those individuals with adherence levels in the 40% to Ͻ80% and 80% to Ͻ95% strata. There were no visible differences in the relationship when the data were stratified by CD4 cell count ( figure 1b) ; however, when stratified by year of first therapy, the data indicated that individuals starting therapy during 1996 -1998 presented the highest probabilities for the development of drug resistance, and this probability decreased linearly until 2002-2004 (figure 1c). Furthermore, stratifying by pVL (figure 1d) demonstrated that individuals in the baseline pVL Ͻ5 log 10 copies/mL stratum had a considerably lower probability for the development of resistance than those with baseline pVL values 5 log 10 copies/mL at equivalent levels of adherence.
Of particular interest is the relationship between emergence of resistance, pVL, and adherence stratified by regimen type (figure 2). The dependence of resistance selection on baseline pVL and patient adherence was markedly decreased for boosted PI-based regimens. The estimated probability of resistance for the worst adherence-pVL stratum for boosted PI-based regimens was equal to or lower than that observed for any adherence stratum for nonboosted PI-based regimens and was very similar to that of NNRTI-based regimens for adherence levels Ͻ80%. For those patients with a pVL in the Ͻ5 log 10 copies/mL range, the risk of the development of drug resistance varied greatly depending on the first regimen. 
Sensitivity analyses.
In the central analysis, samples with a pVL Ͻ1000 copies/mL were not genotyped and were assumed to not carry resistance mutations. We addressed the impact of this assumption by conducting a sensitivity analysis, eliminating those individuals with viral suppression (pVL Ͻ 1000 copies/ mL) during the entire follow-up period (n ϭ 541 [23%]). An explanatory logistic regression model was developed for identifying which patient characteristics were the most influential in the development of drug resistance during antiretroviral treatment. The results from the new univariate analyses were consistent with the previous ones, and the multivariate analysis also yielded results similar to those presented before. Based on the multivariate model, we also observed no difference in the odds of the development of key resistance mutations between nonboosted PI-based regimens (reference group) and NNRTIbased regimens (OR, 1. To address the potential impact of transmitted resistance on resistance that develops during therapy, we conducted another sensitivity analysis examining only those 1426 individuals for whom pretherapy genotypes were available and excluding those who exhibited transmitted resistance (n ϭ 131), leaving a total To address the potential effects of wild-type virus outgrowth in patients who ceased active therapy, we conducted another sensitivity analysis eliminating the 117 individuals who were not receiving any therapy at the time of resistance detection. Overall, we obtained results similar to those of the original analysis and of other sensitivity analyses. Of particular note, the effect of boosted PIs on the OR for resistance was even greater than that in the original analysis (OR, 0.37 [95% CI, 0.24 -0.56]).
DISCUSSION
Our results demonstrate that the probability of emergent drug resistance decreased steadily during 1996 -2004. Incomplete adherence and nonboosted PI-based or NNRTI-based antiretro- , or nonboosted PI), adherence rate (0% to Ͻ40%, 40% to Ͻ80%, 80% to Ͻ95%, or 95%), and plasma HIV-1 RNA load (Ͻ5 or 5 log 10 copies/mL). Data are median values; bars show interquartile ranges. viral regimens were associated with a greater probability of the development of drug resistance. In contrast, boosted PI-based regimens were significantly associated with a lower emergence of resistance, even after adjustment for pVL and CD4 cell count. Of note, the latter remained the case at all levels of adherence.
Suboptimal adherence levels (80% to Ͻ95%) were associated with the highest risk of resistance in any drug category (hazard ratio [HR], 4.15; P Ͻ .001) or in multiple resistance categories (HR, 6.99; P ϭ .010) (survival analysis data not shown). Recent studies have also shown that different ART classes have unique adherence-resistance relationships [17, 18] . Bangsberg et al. [18] , gathering data from several studies, demonstrated that, with regimens containing nonboosted PIs, most drug resistance occurred in patients with adherence levels between 70% and 80%.
The data obtained here show that boosted PI-based regimens are associated with relatively low levels of resistance development across all adherence strata, consistent with previous observations that boosted PI-based regimens may have a more "forgiving" profile in terms of virological suppression [22, 36] . Also, it is interesting to note that we observed a 2-fold increase in the risk of resistance in patients with a history of injection drug use; this contrasts with an only slightly increased risk noted previously [12] . The reasons for this difference are not clear.
There are several features of the present study that should be highlighted. First, this study was based on a large sample of patients within a provincewide treatment program, in which all individuals had free access to medical attention, combination ART, and laboratory monitoring. We are confident, therefore, that our results are not influenced by access to therapy, a factor that has often compromised the interpretation of similar population-and cohort-based studies. Second, the very simple methodology of logistic regression was sufficient to show the simultaneous effects of adherence, pVL, and antiretroviral regimen on the development of drug resistance. Third, this study was based on individuals who were initially naive to ART, ensuring that our results were not confounded by previous therapy use.
There are some important potential limitations in our study. First, study participants who had samples with a pVL Ͻ1000 copies/mL were assumed to have no drug-resistance mutations. To assess whether this introduced a possible source of bias, we conducted a sensitivity analysis excluding these individuals. This analysis showed that this assumption did not bias our results. Second, pretherapy genotypes were not available for the assessment of transmitted resistance in all study participants. We conducted a sensitivity analysis in the subset of individuals who had pretherapy genotypes without transmitted resistance and found that our original findings still held. Third, we used pharmacyrefill compliance as a surrogate for adherence; however, this measure of adherence has been found to be independently associated with HIV suppression and survival among HIV-infected individuals enrolled in the BC-CfE DTP [11, 37] . Fourth, the measure of adherence used in this study was that obtained at the end of the first year of therapy, which is a conservative measure of adherence. Some recent studies have shown that patients change their level of adherence over time, with longer treatments being associated with lower adherence levels [38 -42] . Therefore, it is possible that if we used time-varying adherence we would see an even stronger effect of adherence on the emergence of resistance than that found here. Further investigation of the role played by longitudinal adherence in predicting drug resistance is important in understanding this major contributor to drug resistance. Finally, although we adjusted our analyses for pertinent demographic and clinical characteristics, residual confounding may exist among observational study populations, and for this reason caution is warranted.
In conclusion, we found a complex relationship among adherence, first antiretroviral regimen, pVL, and the probability of the development of drug resistance among naive individuals initiating their first HAART regimen. The data show a clear improvement in the populational levels of HIV drug resistance as patients start more modern HAART regimens. More importantly, our results demonstrate increased resilience to the development of drug resistance with modern boosted PI-based HAART.
